-
公开(公告)号：EP4230162B1
公开(公告)日：2024-10-09
申请号：EP23183741.0
申请日：2013-10-30
IPC分类号： A61M25/04 , A61M25/10 , A61M5/14 , A61B18/02 , A61B18/14 , A61B18/18 , A61B18/24 , A61B18/00 , A61F7/00 , A61F7/12 , A61K47/10 , A61K47/12 , A61K47/14 , A61K49/04 , A61N7/00 , A61B18/04 , A61B17/22 , A61N7/02
CPC分类号： A61M25/1011 , A61M2025/105220130101 , A61K47/10 , A61K47/12 , A61K47/14 , A61B18/0218 , A61B18/18 , A61B2018/0028520130101 , A61B2018/0034520130101 , A61B2018/0048220130101 , A61B2018/0054120130101 , A61B2018/0057720130101 , A61B2018/0099420130101 , A61B2018/021220130101 , A61F2007/006320130101 , A61F2007/009120130101 , A61F2007/12620130101 , A61N2007/004320130101 , A61B18/1492 , A61B18/04 , A61B18/1815 , A61B18/24 , A61B2017/2206720130101 , A61B2018/0051120130101 , A61B2018/026220130101 , A61B2018/04620130101 , A61B2018/04820130101 , A61N7/00 , A61N7/02 , A61P1/00 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/12 , A61P25/00 , A61P25/02 , A61P29/00 , A61P3/04 , A61P35/00 , A61P43/00 , A61P9/04 , A61P9/12 , A61P3/10
-
公开(公告)号：EP4058059B1
公开(公告)日：2024-10-09
申请号：EP20888060.9
申请日：2020-11-13
CPC分类号： A61K39/35 , A61K39/36 , A61K2039/5556620130101 , A61K2039/57720130101 , A61K2039/54320130101 , A61K9/1075 , A61K9/0043 , A61K9/0078 , A61P11/06 , A61P37/08 , B82Y5/00
-
公开(公告)号：EP4417261A3
公开(公告)日：2024-10-02
申请号：EP24168584.1
申请日：2017-04-19
发明人： NEVILLE, Anne , BROWNE, Hilary , FORSTER, Sam , LAWLEY, Trevor
IPC分类号： A61K35/742 , A61P31/04
CPC分类号： A61K35/742 , A61P1/00 , A61P1/04 , A61P1/16 , A61P11/06 , A61P19/02 , A61P25/00 , A61P25/16 , A61P25/28 , A61P3/00 , A61P3/04 , A61P31/04 , A61P35/00 , A61P3/06 , A61P37/02 , A61P37/08 , A61P43/00 , A61P7/00 , A61P9/00 , A61P3/10 , Y02A50/30
摘要： The invention relates to therapeutic compositions comprising at least one isolated bacterium and a pharmaceutically acceptable excipient, as well as methods of preparing such therapeutic compositions. The therapeutic compositions find application in the treatment of dysbiosis, in particular dysbiosis of the gastrointestinal tract.
-
公开(公告)号：EP4434986A1
公开(公告)日：2024-09-25
申请号：EP22894954.1
申请日：2022-11-18
发明人： ZHANG, Xuejun , LI, Xueqiang , WANG, Hongqiang , YE, Dabing , WANG, Meng , AN, Dan , GAO, Zhenxing , ZHAO, Xin , LI, Li'e , YANG, Jun
IPC分类号： C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4375 , A61K31/517 , A61P1/04 , A61P9/00 , A61P1/16 , A61P29/00
CPC分类号： A61K31/437 , A61K31/4375 , A61K31/438 , A61K31/4545 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/10 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P21/00 , A61P25/00 , A61P25/04 , A61P27/02 , A61P27/04 , A61P27/06 , A61P27/16 , A61P29/00 , C07D471/04 , C07D487/04 , C07D519/00
摘要： Provided are a 15-PGDH inhibitor and the use thereof. The 15-PGDH inhibitor is a heterocyclic compound as represented by formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compound has a good inhibitory effect on 15-PGDH.
-
公开(公告)号：EP4433459A1
公开(公告)日：2024-09-25
申请号：EP22818338.0
申请日：2022-11-17
发明人： AITKEN, Lewis Scott , ALANINE, Thomas Alexander , BOUCHE, Lea Aurelie , GUBA, Wolfgang , JAESCHKE, Georg , MESCH, Stefanie Katharina , THOM, Stephen Malcom , TOSSTORFF, Andreas Michael , SCHNIDER, Christian , STEINER, Sandra , HERR, Sabrina
IPC分类号： C07D237/24 , C07D401/12 , C07D471/04 , A61K9/20 , A61K9/48 , A61P11/00 , A61P11/06 , A61P25/16 , A61P25/28 , A61K31/501
CPC分类号： C07D237/24 , C07D401/12 , C07D471/04 , A61P11/00 , A61P11/06 , A61P25/16 , A61P25/28 , A61K9/2054 , A61K9/2059 , A61K9/4866
-
公开(公告)号：EP4433066A1
公开(公告)日：2024-09-25
申请号：EP21892940.4
申请日：2021-11-12
IPC分类号： A61K33/06 , A61K33/30 , A61K33/242 , A61K33/34 , A61K33/244 , A61K33/245 , A61K33/26 , A61K33/241 , A61K33/32 , A61K33/243 , A61K33/38 , A61P3/02
-
公开(公告)号：EP4422673A1
公开(公告)日：2024-09-04
申请号：EP22884793.5
申请日：2022-10-27
申请人： Mucpharm Pty Ltd
发明人： MORRIS, David , VALLE, Sarah , MEKKAWY, Ahmed , PILLAI, Krishna
CPC分类号： A61P29/00 , A61P11/06 , A61P11/00 , A61P11/12 , A61K31/198 , A61K9/0075 , A61K38/4873 , C12Y304/22004 , C12Y304/22002 , C12Y304/22003 , C12Y304/22014 , C12Y304/22067 , C12Y304/22033 , C12Y304/22031 , A61K38/063 , C12Y301/21001 , A61K38/465
-
公开(公告)号：EP4419203A1
公开(公告)日：2024-08-28
申请号：EP22854464.9
申请日：2022-10-17
发明人： MCCARTHY, Tom , NAYLOR, Alan , MILLER, David , MILNE, Gavin , IEVA, Maria , MOCHEL, Tobias , ESVAN, Yannick , FEUTRILL, John
IPC分类号： A61P11/00 , A61P11/06 , A61P35/00 , A61P43/00 , C07D471/18 , A61K31/439
CPC分类号： A61P35/00 , A61P43/00 , A61P11/00 , A61P11/06 , C07D471/18
-
9.发明公开
公开(公告)号：EP4417621A1
公开(公告)日：2024-08-21
申请号：EP22880203.9
申请日：2022-10-08
发明人： SUN, Bing , YI, Chunyan , LING, Zhiyang
CPC分类号： A61K39/42 , A61K47/68 , A61P11/06 , A61P31/14 , C07K19/00 , C12N5/06 , C12N5/10 , C12N15/11 , C07K16/1003
摘要： The present invention provides a design and application of a fully human antibody for neutralizing respiratory syncytial virus. Specifically, in the present invention, germline gene back mutation and affinity enhancement are performed on respiratory syncytial virus fusion protein fully-human monoclonal antibody 4Fl by using computer aided design and site-directed mutagenesis technology. The modified antibody of the present invention has a relatively low number of somatic mutation sites, has high affinity, can effectively prevent RSV infection, and can also effectively inhibit the spread of RSV infection.
-
10.发明授权
公开(公告)号：EP3730188B1
公开(公告)日：2024-07-31
申请号：EP20158694.8
申请日：2016-08-19
-
-
-
-
-
-
-
-
-
搜索结果
204 条记录 (耗时 0.022 秒)
